Biosimilar insulins: Informed choice for South Asia.
作者信息
Kalra Sanjay, Azad Khan A K, Raza Syed Abbas, Somasundaram Noel, Shrestha Dina, Latif Zafar Ahmed, Bajaj Sarita, Pathan Md Faruque, Sahay Rakesh, Mahtab Hajera
机构信息
Department of Endocrinology, Bharti Hospital, Karnal, India.
Diabetic Association of Bangladesh, Bangladesh.
出版信息
Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):5-8. doi: 10.4103/2230-8210.164033.
Abstract
摘要
相似文献
1
Biosimilar insulins: Informed choice for South Asia.
Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):5-8. doi: 10.4103/2230-8210.164033.
2
Biosimilar insulins are coming: the top 10 things you should know.
Postgrad Med. 2014 May;126(3):107-10. doi: 10.3810/pgm.2014.05.2760.
3
Introduction of biosimilar insulins in Europe.
Diabet Med. 2017 Oct;34(10):1340-1353. doi: 10.1111/dme.13400. Epub 2017 Jul 16.
4
Biosimilar vs originator insulins: Systematic review and meta-analysis.
Diabetes Obes Metab. 2018 Jul;20(7):1787-1792. doi: 10.1111/dom.13291. Epub 2018 Apr 17.
5
Biosimilar insulins are coming: what they are, what you need to know.
Curr Med Res Opin. 2014 Nov;30(11):2217-22. doi: 10.1185/03007995.2014.952718. Epub 2014 Aug 20.
6
Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria.
Healthcare (Basel). 2021 Jun 9;9(6):697. doi: 10.3390/healthcare9060697.
7
Update on Biosimilar Insulins: A US Perspective.
BioDrugs. 2020 Aug;34(4):505-512. doi: 10.1007/s40259-020-00431-0.
8
Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.
J Diabetes Sci Technol. 2023 Nov;17(6):1649-1661. doi: 10.1177/19322968221105864. Epub 2022 Jul 11.
9
Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
PLoS One. 2018 Apr 18;13(4):e0195012. doi: 10.1371/journal.pone.0195012. eCollection 2018.
10
Biosimilar insulins: An unavoidable option in South-East Asia.
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):574-5. doi: 10.4103/2230-8210.183462.
引用本文的文献
1
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners.
Adv Ther. 2025 Jun 7. doi: 10.1007/s12325-025-03250-3.
2
Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program.
J Diabetes Investig. 2018 Nov;9(6):1312-1322. doi: 10.1111/jdi.12843. Epub 2018 Apr 24.
本文引用的文献
1
Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.
Eur Endocrinol. 2015 Apr;11(1):10-16. doi: 10.17925/EE.2015.11.01.10. Epub 2015 Apr 11.
2
The advent of biosimilars for the treatment of diabetes: current status and future directions.
Acta Diabetol. 2015 Jun;52(3):423-31. doi: 10.1007/s00592-015-0771-7. Epub 2015 May 20.
3
Biosimilar insulins: guidance for data interpretation by clinicians and users.
Diabetes Obes Metab. 2015 Oct;17(10):911-8. doi: 10.1111/dom.12491. Epub 2015 Jul 1.
4
Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015.
Indian J Endocrinol Metab. 2015 May-Jun;19(3):317-31. doi: 10.4103/2230-8210.152762.
5
Hypersensitivity reaction to a biosimilar insulin glargine.
J Diabetes. 2015 Mar;7(2):155-7. doi: 10.1111/1753-0407.12241. Epub 2015 Jan 7.
6
FDA-approved biosimilar insulin: good enough for critical care, adulterated, or counterfeit? How can we tell?
J Diabetes Sci Technol. 2014 Sep;8(5):1052-4. doi: 10.1177/1932296814539275. Epub 2014 Jun 16.
7
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report.
J Diabetes Sci Technol. 2014 Jan;8(1):179-185. doi: 10.1177/1932296813518267. Epub 2014 Jan 1.
8
Patient Perspectives on Biosimilar Insulin.
J Diabetes Sci Technol. 2014 Jan;8(1):23-25. doi: 10.1177/1932296813515132. Epub 2014 Jan 1.
9
Multiple Source Biosimilar Insulin, What's a Provider to Do?
J Diabetes Sci Technol. 2014 Jan;8(1):20-22. doi: 10.1177/1932296813511748. Epub 2014 Jan 1.
10
Drug Development and Potential Regulatory Paths for Insulin Biosimilars.
J Diabetes Sci Technol. 2014 Jan;8(1):14-19. doi: 10.1177/1932296813516954. Epub 2014 Jan 1.
Zotero 插件